Edwards Lifesciences
30 named things its latest annual report says its results depend on, each in the company's own words. 25 of them are also named by other companies we've read.
Customers
Group purchasing organizations (GPOs)
earns fromnamed as a riskIf we are not one of the providers selected by one of these organizations, we may be precluded from making sales to its members or participants.Risk factors (Item 1A)
Also named by BAX, BDX, BSX, CDW, GMED, GWW, SYY, USFD and 1 more
U.S. Veterans Administration
earns fromnamed as a riskThe health care industry has been consolidating, and organizations such as GPOs, independent delivery networks, and large single accounts, such as the United States Veterans Administration, continue to consolidate purchasing decisions for many of our health care provider customers.Risk factors (Item 1A)
Other companies
Competitors
Medtronic plc
competes withnamed as a riskIn TAVR, our primary competitors include Medtronic plc (“Medtronic”) and Abbott Laboratories (“Abbott”).Business (Item 1)
Abbott Laboratories
competes withnamed as a riskIn TMTT, our primary competitor is Abbott, and there are a considerable number of large and small companies with development efforts in these fields.Business (Item 1)
Also named by DXCM
Places
United States
earns from · 58% of our net salesIn 2025, 58% of our net sales were derived from sales to customers in the United States.Business (Item 1)
Also named by ABBV, ADP, AJG, AMGN, APA, AXGN, AXP, BALL and 139 more
Europe
earns from · 60%Of the total sales outside of the United States, 60% were in Europe, 14% were in Japan, and 26% were in Rest of World.Business (Item 1)
Also named by ADSK, AME, AMRC, ATR, BCSF, BKNG, BMI, BMY and 60 more
Japan
earns from · 14%Of the total sales outside of the United States, 60% were in Europe, 14% were in Japan, and 26% were in Rest of World.Business (Item 1)
Also named by A, AAPL, AFL, AMKR, ANET, BMY, BSX, CAT and 25 more
Switzerland
operates innamed as a riskIn addition, in the EU, we import some of our devices through our offices in Switzerland.Risk factors (Item 1A)
Israel
operates inOur research and development activities are conducted primarily in facilities located in the United States and Israel.Business (Item 1)
Also named by AIOT, AKAM, AMAT, AMGN, APP, ASTS, AVY, BSX and 31 more
Australia
depends onWe obtain bovine tissue used in our pericardial tissue valve products only from sources within the United States and Australia, where strong control measures and surveillance programs exist.Business (Item 1)
Also named by AJG, ARWR, AXP, BF/B, BTU, CL, CSGP, CVX and 15 more
Ireland
operates inWe manufacture our TAVR, TMTT, and Surgical products primarily in the United States, Singapore, Costa Rica, and Ireland, to ensure continuity of care for patients in these regions and also worldwide.Business (Item 1)
Also named by AAPL, ACN, ADI, AGX, BEN, CDNS, CELH, COR and 13 more
Singapore
operates inWe manufacture our TAVR, TMTT, and Surgical products primarily in the United States, Singapore, Costa Rica, and Ireland, to ensure continuity of care for patients in these regions and also worldwide.Business (Item 1)
Also named by A, AAPL, ALAB, AMAT, ANET, APP, AVGO, DLR and 12 more
Hazards
Earthquakes
operates innamed as a riskDisruptions can also occur if our manufacturing and warehousing facilities are damaged by earthquakes, hurricanes, volcanoes, fires, and other natural disasters or catastrophic circumstances.Risk factors (Item 1A)
Also named by AAPL, AMKR, AN, ANET, APP, BRO, CDNS, CEG and 37 more
Bovine spongiform encephalopathy (BSE)
named as a riskConcerns relating to the potential transmission of animal-borne illnesses, including BSE, commonly known as “mad cow disease,” from cows to humans may result in reduced acceptance of products containing bovine materials.Risk factors (Item 1A)
Also named by JBTM
Commodities and inputs
Euro
exposed to its pricenamed as a riskOur principal currency exposures relate to the Euro and the Japanese yen.Market risk (Item 7A)
Also named by ABBV, ABNB, ABT, ADBE, ADI, AME, AMG, AMGN and 186 more
Japanese yen
exposed to its pricenamed as a riskOur principal currency exposures relate to the Euro and the Japanese yen.Market risk (Item 7A)
Also named by ABBV, ABT, ACN, ADBE, ALK, AMAT, AMKR, BMY and 24 more
Bovine tissue
depends onnamed as a riskWe obtain bovine tissue only from closely controlled sources within the United States and Australia.Risk factors (Item 1A)
Regulators
U.S. Food and Drug Administration (FDA)
subject tonamed as a riskA prolonged government shutdown could significantly affect the FDA’s timely review of any regulatory filings or applications we submit, which could result in delays or failures to obtain or maintain regulatory approvals, clearances or to comply with regulatory requirements.Risk factors (Item 1A)
Also named by A, ABBV, ABT, AMGN, ARE, ARWR, ATR, AXGN and 112 more
Centers for Medicare & Medicaid Services (CMS)
subject tonamed as a riskChanges in current coverage and reimbursement levels could have an adverse effect on market demand and our pricing flexibility.Business (Item 1)
Also named by A, ABT, AMGN, AXGN, BAX, BWIN, CNC, COO and 23 more
Japanese Ministry of Health, Labour and Welfare
subject tonamed as a riskApproval time frames from the Japanese Ministry of Health, Labour and Welfare vary from simple notifications to review periods of one or more years, depending on the complexity and risk level of the device.Business (Item 1)
Medicines and Healthcare products Regulatory Agency (MHRA)
subject toCurrently, the UK’s medical device legislation states that the access for CE-marked medical devices will end on June 30, 2030; however, the UK’s regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA), has announced it will consult on extending the recognition of CE-marked products indefinitely.Business (Item 1)
Laws and programs
Medicare
earns fromnamed as a riskHHS' Centers for Medicare & Medicaid Services (“CMS”) may also review whether and/or under what circumstances a procedure or technology is reimbursable for Medicare beneficiaries.Business (Item 1)
Also named by ABT, ARWR, AXGN, BAX, BDX, BMY, BSX, CAH and 48 more
OECD Pillar Two
subject tonamed as a riskThe effective dates of implementation, the interactions of tax reforms in multiple jurisdictions, uncertainty related to dispute resolution mechanisms, and any ultimate agreement regarding treatment of the U.S. tax regime as a qualified side-by-side Pillar Two system, could impact our provision for income taxes.Risk factors (Item 1A)
Also named by APO, BAM, BAX, BF/B, CHRW, COHR, CPNG, CRM and 45 more
Affordable Care Act
subject tonamed as a riskFor example, in the United States, continued implementation of the Affordable Care Act and the 21st Century Cures Act, or any future legislation, including deficit reduction legislation, could impact medical procedure volumes, reimbursement for our products, and demand for our products or the prices at which we sell our products.Risk factors (Item 1A)
Also named by ABBV, ABT, ADP, AFL, BBSI, BRO, BWIN, COR and 8 more
EU Medical Device Regulation (MDR)
subject tonamed as a riskDuring the transition period, with the influx of submissions to the notified bodies, any delay on obtaining approvals may result in a disruption of device supply or a further delay in getting a device to market.Risk factors (Item 1A)
Also named by ABBV, BAX, BDX, BSX, CAH, COO, DXCM, GEHC and 4 more
U.S. Section 232 investigation on medical devices
subject tonamed as a riskAdditionally, the U.S. Department of Commerce recently initiated an investigation under Section 232 of the Trade Expansion Act of 1962, as amended, into (among other things) imports of personal protective equipment, medical consumables and medical equipment (including devices), to determine whether they threaten U.S. national security, which further creates policy uncertainty in terms of tariffs.Risk factors (Item 1A)
Also named by BDX
EU-Switzerland Mutual Recognition Agreement
subject tonamed as a riskIn addition, a Mutual Recognition Agreement still under negotiation for the Medical Device Regulation may result in a lack of free movement of medical devices between the EU and Switzerland, may impact our access in the EU and may, ultimately, have a material effect on our business, financial condition, and results of operations.Risk factors (Item 1A)
U.S. national coverage determination for TAVR
subject tonamed as a riskEven if we timely innovate and develop products, our ability to successfully market them could be limited by a number of different factors, including competitive products and pricing, barriers in patient activation (including disease awareness, detection, and diagnosis), restrictive requirements in the U.S. national coverage determination for transcatheter aortic valve replacement procedures, the need for regulatory clearance, restrictions imposed on approved indications, capacity constraints within hospital systems, including staffing shortages and the availability of catheterization laboratories, and uncertainty over third-party reimbursement.Risk factors (Item 1A)